IL-33 Targeting Shows Promise in COPD Treatment, Questions Remain
Recent studies suggest that targeting IL-33 can significantly reduce COPD exacerbations, but the effectiveness across various patient profiles is still unclear.
NEW DELHI, Nov 8: Targeting interleukin-33 (IL-33) may enhance treatment options for chronic obstructive pulmonary disease (COPD) patients, according to recent findings. IL-33-targeted therapy could potentially benefit a larger population than current treatments, which rely on eosinophil counts to determine eligibility.
Francesca Polverino, MD, PhD, from Baylor College of Medicine, discussed the implications of these findings during the GOLD 2026 COPD International Conference in Philadelphia. She stated that existing biologic therapies primarily assist about 20% of COPD patients who have elevated eosinophil counts. In contrast, IL-33’s prevalence in the blood and lungs of many COPD patients suggests that a drug targeting this pathway could reach a broader patient base.
In two Phase III trials, OBERON and TITANIA, an investigational monoclonal antibody targeting IL-33 significantly reduced moderate-to-severe exacerbations in COPD patients who still experienced flare-ups during ongoing maintenance therapy. The trials showed a 29% to 34% reduction in exacerbation rates among former smokers receiving the IL-33 treatment compared to those on placebo.
- In OBERON, annualised exacerbation rates were 1.34 events per patient-year in the treatment group, versus 1.90 in placebo.
- TITANIA showed rates of 1.37 for the treatment group and 2.07 for placebo.
Researchers noted that these reductions reflect relative rates rather than the percentage of patients avoiding exacerbations altogether. Importantly, both trials allowed patient enrollment regardless of eosinophil counts, which broadens the applicability of the results.
These promising outcomes raise questions regarding the drug’s effects across different eosinophil subgroups. The trials did not clarify whether the treatment worked uniformly among all patients or if specific characteristics influenced responses to the therapy.
Polverino emphasized the need for additional research to explore how different forms of IL-33 might be targeted. Current studies indicate that IL-33 exists in both reduced and oxidized forms, each playing different roles in COPD. More data is necessary to determine whether different therapies can effectively target these forms.
“The ability to treat across the eosinophil spectrum is a central advance offered by the IL-33 pathway,” Polverino said.
In terms of safety, adverse events were comparable between treatment and placebo groups. In OBERON, 70.4% of patients on the IL-33 treatment experienced adverse events, compared with 77.2% on placebo. For TITANIA, rates were 80.1% and 79.8%, respectively.
The findings underscore the potential of IL-33-targeted therapies as an additional strategy in managing COPD, particularly for patients struggling with persistent exacerbations despite standard care.
Sources
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.